PMID- 29608505
OWN - NLM
STAT- MEDLINE
DCOM- 20181113
LR  - 20210504
IS  - 1538-4683 (Electronic)
IS  - 1061-5377 (Linking)
VI  - 26
IP  - 6
DP  - 2018 Nov/Dec
TI  - Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review 
      of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit.
PG  - 312-320
LID - 10.1097/CRD.0000000000000201 [doi]
AB  - Cardiovascular (CV) disease remains the leading cause of morbidity and mortality 
      in individuals with type 2 diabetes mellitus (T2DM). However, conventional 
      antihyperglycemic medications seem to have minimal effect on lowering CV risk 
      despite achieving excellent reductions in glycated hemoglobin A1c and associated 
      reductions in microvascular risk. Sodium-glucose cotransporter 2 (SGLT2) 
      inhibitors have emerged as noteworthy antihyperglycemic agents with concomitant 
      CV and renal protection in T2DM patients. In this comprehensive review, we 
      present the key CV findings from major large-scale outcome trials of SGLT2 
      inhibitors to date. We also review the mechanistic studies that might explain the 
      CV benefits of SGLT2 inhibition in patients with T2DM.
FAU - Dalan, Rinkoo
AU  - Dalan R
AD  - From the Department of Endocrinology, Division of Medicine, Tan Tock Seng 
      Hospital, Singapore; Department of Metabolic Medicine, Lee, Kong Chian School of 
      Medicine, Nanyang Technological University, Singapore; and Department of General 
      Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 
      Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiol Rev
JT  - Cardiology in review
JID - 9304686
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Blood Glucose/drug effects/metabolism
MH  - Cardiovascular Diseases/etiology
MH  - *Diabetes Mellitus, Type 2/blood/complications/drug therapy
MH  - Global Health
MH  - Glucosides/*therapeutic use
MH  - Humans
MH  - Morbidity/trends
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Survival Rate/trends
EDAT- 2018/04/03 06:00
MHDA- 2018/11/14 06:00
CRDT- 2018/04/03 06:00
PHST- 2018/04/03 06:00 [pubmed]
PHST- 2018/11/14 06:00 [medline]
PHST- 2018/04/03 06:00 [entrez]
AID - 10.1097/CRD.0000000000000201 [doi]
PST - ppublish
SO  - Cardiol Rev. 2018 Nov/Dec;26(6):312-320. doi: 10.1097/CRD.0000000000000201.